Gilead Sciences’ Truvada approved in Europe for PrEP indication

Gilead Sciences has announced that its HIV therapy Truvada has been approved as a means of reducing the risk of sexually-acquired HIV-1.

The emtricitabine/tenofovir disoproxil therapy has been approved in combination with safer-sex practices to reduce the risk of sexually acquired HIV infection among uninfected adults at high risk – a strategy known as pre-exposure prophylaxis (PrEP).

Truvada was originally approved in Europe in 2005 for use in combination with other antiretroviral agents for the treatment of HIV infection in adults and is currently the most prescribed antiretroviral medicine in Europe as part of combination therapy.

Global clinical guidelines support the use of PrEP, in combination with other prevention measures such as condoms, to prevent the sexual transmission of high-risk patients.

Dr Norbert Bischofberger, executive vice-president for research and development and chief scientific officer at Gilead Sciences, said: "When taken as directed and used in combination with other prevention strategies, Gilead believes Truvada for PrEP can have a meaningful impact on public health by helping to reduce HIV transmission rates across Europe."

This comes after a recent landmark ruling from the High Court deemed NHS England has the legal power to commission a PrEP service in the UK utilising therapies such as Truvada.

With? ?over? ?20? ?years? ?of? ?experience? ?within? ?the? ?pharmaceutical? ?market,? ?we? ?at? ?Zenopa? ?have? ?the knowledge,? ?skills? ?and? ?expertise? ?to? ?help? ?find? ?the? ?right? ?job? ?for? ?you.? ?To? ?find? ?out? ?more? ?about? ?the current? ?pharmaceutical? ?roles? ?we? ?have? ?available,? ?you? ?can? ?search? ?for? ?the? ?latest? ?job? ?roles, register? ?your? ?details,? ?or? ?contact? ?the? ?team? ?today.